RESEARCH ARTICLE
Assessing Walking Ability in People with HTLV-1-Associated Myelopathy Using the 10 Meter Timed Walk and the 6 Minute Walk Test Adine Adonis1*, Graham P. Taylor1,2 1 National Centre for Human Retrovirology, St Mary’s Hospital, Imperial College Healthcare NHS Trust, London, W2 1NY, United Kingdom, 2 Section of Virology, Department of Medicine, Imperial College, London, W2 1PG, United Kingdom * [email protected]
a11111
Abstract Background OPEN ACCESS Citation: Adonis A, Taylor GP (2016) Assessing Walking Ability in People with HTLV-1-Associated Myelopathy Using the 10 Meter Timed Walk and the 6 Minute Walk Test. PLoS ONE 11(6): e0157132. doi:10.1371/journal.pone.0157132 Editor: Diego Fraidenraich, Rutgers University -New Jersey Medical School, UNITED STATES Received: November 23, 2015
Five to ten million persons, are infected by HTLV-1 of which 3% will develop HTLV-1-associated myelopathy (HAM) a chronic, disabling inflammation of the spinal cord. Walking, a fundamental, complex, multi-functional task is demanding of multiple body systems. Restricted walking ability compromises activity and participation levels in people with HAM (pwHAM). Therapy aims to improve mobility but validated measures are required to assess change.
Study Design Prospective observational study.
Accepted: May 25, 2016 Published: June 23, 2016
Objectives
Copyright: © 2016 Adonis, Taylor. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
To explore walking capacity in pwHAM, walking endurance using the 6 minute walk (6MW), and gait speed, using the timed 10m walk (10mTW).
Data Availability Statement: Data are restricted from public sharing due to patient identifying information. The supporting data underlying this publication can be requested by contacting [email protected].
Setting Out-patient setting in an inner London Teaching hospital.
Methods Prospective documentation of 10mTW and 6MW distance; walking aid usage and pain scores measured twice, a median of 18 months apart.
Funding: The authors have no support or funding to report.
Results
Competing Interests: The authors have declared that no competing interests exist.
Data analysis was completed for twenty-six pwHAM, (8♂; 18♀; median age: 57.8 years; median disease duration: 8 years). Median time at baseline to: complete 10m was 17.5
PLOS ONE | DOI:10.1371/journal.pone.0157132 June 23, 2016
1 / 12
Walking Capacity in HTLV-1 Associated Myelopathy
seconds, versus 21.4 seconds at follow up; 23% completed the 6MW compared to 42% at follow up and a median distance of 55m was covered compared to 71m at follow up. Using the 10mTW velocity to predict the 6MW distance, overestimated the distance walked in 6 minutes (p
Assessing Walking Ability in People with HTLV-1-Associated Myelopathy Using the 10 Meter Timed Walk and the 6 Minute Walk Test Adine Adonis1*, Graham P. Taylor1,2 1 National Centre for Human Retrovirology, St Mary’s Hospital, Imperial College Healthcare NHS Trust, London, W2 1NY, United Kingdom, 2 Section of Virology, Department of Medicine, Imperial College, London, W2 1PG, United Kingdom * [email protected]
a11111
Abstract Background OPEN ACCESS Citation: Adonis A, Taylor GP (2016) Assessing Walking Ability in People with HTLV-1-Associated Myelopathy Using the 10 Meter Timed Walk and the 6 Minute Walk Test. PLoS ONE 11(6): e0157132. doi:10.1371/journal.pone.0157132 Editor: Diego Fraidenraich, Rutgers University -New Jersey Medical School, UNITED STATES Received: November 23, 2015
Five to ten million persons, are infected by HTLV-1 of which 3% will develop HTLV-1-associated myelopathy (HAM) a chronic, disabling inflammation of the spinal cord. Walking, a fundamental, complex, multi-functional task is demanding of multiple body systems. Restricted walking ability compromises activity and participation levels in people with HAM (pwHAM). Therapy aims to improve mobility but validated measures are required to assess change.
Study Design Prospective observational study.
Accepted: May 25, 2016 Published: June 23, 2016
Objectives
Copyright: © 2016 Adonis, Taylor. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
To explore walking capacity in pwHAM, walking endurance using the 6 minute walk (6MW), and gait speed, using the timed 10m walk (10mTW).
Data Availability Statement: Data are restricted from public sharing due to patient identifying information. The supporting data underlying this publication can be requested by contacting [email protected].
Setting Out-patient setting in an inner London Teaching hospital.
Methods Prospective documentation of 10mTW and 6MW distance; walking aid usage and pain scores measured twice, a median of 18 months apart.
Funding: The authors have no support or funding to report.
Results
Competing Interests: The authors have declared that no competing interests exist.
Data analysis was completed for twenty-six pwHAM, (8♂; 18♀; median age: 57.8 years; median disease duration: 8 years). Median time at baseline to: complete 10m was 17.5
PLOS ONE | DOI:10.1371/journal.pone.0157132 June 23, 2016
1 / 12
Walking Capacity in HTLV-1 Associated Myelopathy
seconds, versus 21.4 seconds at follow up; 23% completed the 6MW compared to 42% at follow up and a median distance of 55m was covered compared to 71m at follow up. Using the 10mTW velocity to predict the 6MW distance, overestimated the distance walked in 6 minutes (p
